Drug Profile
Selective estrogen receptor modulator - Merck & Co
Alternative Names: SERM - MerckLatest Information Update: 12 Jan 2022
Price :
$50
*
At a glance
- Originator Karo Bio
- Developer Merck & Co
- Class
- Mechanism of Action Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 10 Jul 2007 Discontinued - Phase-I with second unnamed SERM compound for Undefined women's health indication in USA (PO)
- 12 Sep 2006 Phase-I clinical trials with second unnamed SERM compound for Undefined women's health indication in USA (PO)